KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Globus Medical (GMED) Cost of Revenue (2016 - 2025)

Globus Medical (GMED) has disclosed Cost of Revenue for 15 consecutive years, with $261.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cost of Revenue fell 0.88% year-over-year to $261.1 million, compared with a TTM value of $957.8 million through Dec 2025, down 7.5%, and an annual FY2025 reading of $957.8 million, down 7.5% over the prior year.
  • Cost of Revenue was $261.1 million for Q4 2025 at Globus Medical, up from $252.5 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $270.5 million in Q3 2024 and bottomed at $55.0 million in Q1 2021.
  • Average Cost of Revenue over 5 years is $152.2 million, with a median of $105.9 million recorded in 2023.
  • The sharpest move saw Cost of Revenue skyrocketed 276.09% in 2023, then fell 19.09% in 2025.
  • Year by year, Cost of Revenue stood at $61.8 million in 2021, then increased by 14.23% to $70.6 million in 2022, then surged by 276.09% to $265.5 million in 2023, then dropped by 0.77% to $263.4 million in 2024, then dropped by 0.88% to $261.1 million in 2025.
  • Business Quant data shows Cost of Revenue for GMED at $261.1 million in Q4 2025, $252.5 million in Q3 2025, and $248.8 million in Q2 2025.